Novavax (NVAX): This should be the next trial we hear about after Johnson & Johnson reports, and a lot of people are waiting to see how this recombinant protein candidate works out. These will be results from a trial in the UK - a US Phase 3 just launched this week. This one has much less rigorous storage requirements and is generally easier to manufacture, and it could be a big contributor if things work out.
Market Data 
Markets 
AI
